

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

August 5, 2026

To

BSE Limited

Phiroze Jeejeebhoy Towers, 25th Floor, Dalal
Street, Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors at their meeting held on even date, i.e. August 5, 2026, have considered and approved the following:

A. Financial Results

Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30, 2026. A copy of the Unaudited Financial Results for the quarter ended June 30, 2026, together with the limited review reports (Standalone & Consolidated) by the Statutory Auditors of the Company are enclosed herewith.

- B. Execution of deed of Corporate Guarantee for ₹ 40 crores in favour of Gland Pharma Limited in connection with the obligations of the Company under a Loan Licence Agreement to be entered into with Gland Pharma Limited to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. The requisite details are as under:**

Particulars	Details
Name of party for which guarantee Given	Gland Pharma Limited
Whether the promoter/ promoter group have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No, the promoter/ promoter group do not have any interest in this transaction
Brief details of such guarantee viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee;	The Company will be executing an irrevocable, unconditional and continuing Corporate Guarantee of Rs. 40 crores in favour of Gland Pharma Limited in connection with the obligations of the Company under a Loan Licence Agreement to be entered into with Gland Pharma Limited. Under the Loan Licence Agreement, Gland Pharma Limited has agreed to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. The Corporate Guarantee secures the due payment and performance by the Company of its obligations under the Loan Licence Agreement.
Impact of such guarantees or indemnity or surety on listed entity	There is no immediate impact on the financials of the Company. The corporate guarantee represents a contingent liability for the Company.

A Press Release on the above is enclosed as **Annexure A**



- C. Enhancement of manufacturing capacity at Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. The requisite details are as under:

a. Existing Capacity (Unit 1)	376.5 KL
b. Existing Capacity Utilization	91%
c. Proposed Capacity Addition	18 KL
d. Period within which the proposed capacity is to be added	6 - 7 Months
e. Investment required	₹ 39.8 crores (incl GST)
f. Mode of financing	Through internal accruals
g. Rationale	To maintain and cater to the growing demand of our customers

The meeting of Board of Directors of the Company commenced at 10:00 a.m. and concluded at 3.42 p.m.


The above information will also be available on the website of the Company at www.neulandlabs.com.

This is for your information and records.

Thanking you,

Yours Sincerely,

For Neuland Laboratories Limited


Sarada Bhamidipati
Company Secretary

Encl: As above

Independent Auditor's Review Report on consolidated unaudited financial results of Neuland Laboratories Limited for the quarter ended June 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Neuland Laboratories Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Neuland Laboratories Limited ("the Holding Company"), its subsidiaries, (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS 34") and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Neuland Laboratories K.K., Japan	Wholly Owned Subsidiary
2	Neuland Laboratories Inc., USA	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

6. The Statement includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflects total revenue of Rs. 606.54 lakhs, total net profit after tax of Rs. 31.12 lakhs and total comprehensive income of Rs. 22.22 lakhs for the quarter ended June 30, 2026, as considered in the Statement. This interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.


Our conclusion is not modified in respect of the above matter with respect to our reliance on the interim financial information certified by the management.

For M S K A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

ICAI Firm Registration No.105047W/W101187



Prakash Chandra Bhutada

Partner

Membership No.: 404621

UDIN:26404621DSTMOV8687

Place: Hyderabad

Date: August 05, 2026



CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

NEULAND LABORATORIES LIMITED
11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III,
Road No 82, Jubilee Hills, Hyderabad - 500033
STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended			Year Ended
		30.06.2026 (Unaudited)	31.03.2026 (Audited) Refer Note 6	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	Income				
	(a) Revenue from operations	64,157.71	77,625.03	29,275.27	2,02,298.54
	(b) Other income	849.17	1,245.82	785.59	3,016.62
	Total Income	65,006.88	78,870.85	30,060.86	2,05,315.16
2	Expenses				
	(a) Cost of materials consumed	22,876.92	23,078.87	16,148.04	81,976.45
	(b) Changes in inventories of finished goods and work-in-progress	(774.54)	3,850.21	(4,793.65)	(6,426.23)
	(c) Employee benefits expense	10,642.92	9,847.17	7,346.51	34,114.14
	(d) Finance costs	697.19	720.51	458.49	2,394.74
	(e) Depreciation and amortisation expenses	2,656.32	2,508.89	2,018.95	9,173.95
	(f) Manufacturing expenses	4,793.57	5,172.22	3,937.48	19,161.44
	(g) Other expenses	4,329.80	4,943.50	3,188.00	16,022.96
	Total expenses	45,222.18	50,121.37	28,303.82	1,56,417.45
3	Profit before tax (1-2)	19,784.70	28,749.48	1,757.04	48,897.71
4	Tax expense				
	(a) Current tax	5,088.03	7,682.21	436.68	12,895.54
	(b) Deferred tax credit	(70.64)	(199.99)	(69.64)	(397.67)
5	Profit for the period / year (3-4)	14,767.31	21,267.26	1,390.00	36,399.84
6	Other comprehensive income/(loss) (net of taxes)				
	(a) Items that will not be reclassified to profit or loss				
	Re-measurement gain on defined benefit plans	-	65.65	-	1.65
	Changes in fair value of equity instruments through other comprehensive income	-	45.33	-	45.33
	Tax on items that will not be reclassified to profit or loss	-	(27.93)	-	(11.82)
	(b) Items that will be reclassified to profit or loss				
	Exchange differences in translating the financial statements of foreign operations	(8.90)	40.61	9.92	71.25
	Total comprehensive income	14,758.41	21,390.92	1,399.92	36,506.25
7	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
8	Other equity (excluding revaluation reserve)	-	-	-	1,86,073.35
9	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	Basic and Diluted (Refer Note 5)	115.10	165.76	10.83	283.71
	See accompanying notes to the financial results				



NOTES:

- 1 The financial results for the quarter ended June 30, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 05, 2026.
- 2 The financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The consolidated financial results include results of the following wholly owned subsidiaries:
 - (a) Neuland Laboratories Inc., USA
 - (b) Neuland Laboratories KK., Japan.

4 Segment Reporting

Particulars	Quarter Ended			Year Ended
	30.06.2026 (Unaudited)	31.03.2026 (Audited) Refer Note 6	30.06.2025 (Unaudited)	31.03.2026 (Audited)
Segment Revenue				
India	8,326.38	12,150.46	9,892.62	48,409.19
Europe	30,345.81	29,661.19	9,441.22	67,544.32
USA and North America	19,967.36	31,366.44	6,578.38	71,345.10
Rest of the world	5,518.16	4,446.94	3,363.05	14,999.93
Revenue from Operations	64,157.71	77,625.03	29,275.27	2,02,298.54

Particulars	As At	
	30.06.2026	31.03.2026
Segment Non-current assets		
India	1,52,574.60	1,43,305.04
USA and North America	-	-
Rest of the world	2.51	2.82
Total	1,52,577.11	1,43,307.86

i. Segment information presented for the "Consolidated financial results" as permitted under the Ind AS - 'Operating Segments'.

ii. The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS 108 'Operating Segment' and believes that the Group has only one reportable segment namely "manufacture of active pharmaceutical ingredients and allied services". Geography-wise details of the Company's revenues from external customers and its non-current assets (excluding financial assets) are disclosed above.

- 5 The EPS for quarters has not been annualised.
- 6 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and published unaudited figures upto nine months of the relevant financial year.


Place: Hyderabad
Date: August 05, 2026



For Neuland Laboratories Limited



Dr. D R Rao
Executive Chairman
(DIN 00107737)




Independent Auditor's Review Report on Standalone unaudited financial results of Neuland Laboratories Limited for the quarter ended June 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Neuland Laboratories Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Neuland Laboratories Limited ("the Company") for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS 34") and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187


Prakash Chandra Bhutada
Partner
Membership No.: 404621

UDIN:26404621RYVQKG9911

Place: Hyderabad
Date: August 05, 2026



CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

NEULAND LABORATORIES LIMITED
11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III,
Road No 82, Jubilee Hills, Hyderabad - 500033
STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended		Year Ended	
		30.06.2026 (Unaudited)	31.03.2026 (Audited) (Refer Note 5)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	Income				
	(a) Revenue from operations	64,157.71	77,625.03	29,275.27	2,02,298.54
	(b) Other income	849.17	1,245.69	785.59	3,016.39
	Total Income	65,006.88	78,870.72	30,060.86	2,05,314.93
2	Expenses				
	(a) Cost of materials consumed	22,876.92	23,078.87	16,148.04	81,976.45
	(b) Changes in inventories of finished goods and work-in-progress	(774.54)	3,850.21	(4,793.65)	(6,426.23)
	(c) Employee benefits expense	10,302.43	9,526.59	7,088.24	32,882.04
	(d) Finance costs	697.19	723.09	458.33	2,394.54
	(e) Depreciation and amortisation expenses	2,656.09	2,508.67	2,018.72	9,173.05
	(f) Manufacturing expenses	4,793.57	5,172.22	3,937.48	19,161.44
	(g) Other expenses	4,701.64	5,306.78	3,465.90	17,380.33
	Total expenses	45,253.30	50,166.43	28,323.06	1,56,541.62
3	Profit before tax (1-2)	19,753.58	28,704.29	1,737.80	48,773.31
4	Tax expense				
	(a) Current tax	5,088.03	7,679.84	436.68	12,888.35
	(b) Deferred tax credit	(70.64)	(227.86)	(69.64)	(425.54)
5	Profit for the period / year (3-4)	14,736.19	21,252.31	1,370.76	36,310.50
6	Other comprehensive income (net of taxes)				
	Items that will not be reclassified to profit or loss				
	Re-measurement gain on defined benefit plans	-	65.65	-	1.65
	Changes in fair value of equity instruments through other comprehensive income	-	45.33	-	45.33
	Tax on items that will not be reclassified to profit or loss	-	(27.93)	-	(11.82)
	Total comprehensive income	14,736.19	21,335.36	1,370.76	36,345.66
7	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
8	Other equity (excluding revaluation reserve)	-	-	-	1,85,211.19
9	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	Basic and Diluted (Refer Note 4)	114.86	165.65	10.68	283.01
	See accompanying notes to the financial results				

NOTES:

- The financial results for the quarter ended June 30, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 05, 2026.
- The financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments". In accordance with Ind AS 108 - 'Operating segments', segment information has been given in the unaudited consolidated financial results of the Company and therefore no separate disclosure on segment information is given in these unaudited standalone financial results.
- The EPS for quarters has not been annualised.
- The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year March 31, 2026 and published unaudited figures upto nine months of the relevant financial year.

Place: Hyderabad
Date: August 05, 2026



For Neuland Laboratories Limited

Dr. D R Rao

Dr. D R Rao
Executive Chairman
(DIN 00107737)



Neuland Laboratories and Gland Pharma Announce Strategic Collaboration for Sterile API Manufacturing

Partnership to expand sterile API manufacturing through a new, cGMP state-of-the-art sterile suite

Hyderabad, India, 5th August 2026 – Neuland Laboratories Limited ("Neuland") and Gland Pharma Limited ("Gland Pharma") today announced a long-term strategic CDMO partnership. Under the partnership Gland will establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products. The collaboration combines Neuland's Complex API development and manufacturing capabilities including deep expertise in complex chemistry, process development, custom manufacturing having a strong track record of serving global innovator and generic pharmaceutical companies; with Gland Pharma's global sterile manufacturing expertise and strong regulatory compliance track record, to serve growing worldwide demand for sterile APIs used in microparticle depot products and other complex sterile APIs.

The collaboration represents a significant expansion of the relationship between the two companies, creating a dedicated manufacturing platform that aligns their complementary capabilities under a long-term strategic partnership. Under the collaboration, Gland Pharma will expand its existing sterile manufacturing infrastructure through an additional dedicated suite at its JNPC facility at Visakhapatnam to support Neuland for its growing demand of sterile APIs. The facility will be constructed and operated to cGMP, USFDA and EU standards, and will be backed by Gland Pharma's proven aseptic manufacturing expertise. Together, the companies will offer an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs. The suite will be designed to add approximately 1400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth.

The partnership is expected to enhance supply resilience globally by combining Neuland's development and regulatory expertise with Gland Pharma's manufacturing capabilities.

Mr. Saharsh Davuluri, CEO & MD, Neuland Laboratories Limited, said:

"Demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies. Through this partnership with Gland Pharma, we are combining Neuland's expertise in complex APIs with Gland's proven sterile manufacturing capabilities to create a differentiated platform for global customers. Together, we are strengthening our ability to deliver the quality, reliability, and supply assurance that innovators and generic companies expect from their CDMO partners."

Mr. Srinivas Sadu, Executive Chairman, Gland Pharma Limited, said:

"We are pleased to further strengthen our collaboration with Neuland through this strategic partnership. This investment expands our capabilities in sterile API manufacturing and supports increasing customer demand. By leveraging the complementary strengths of both organizations, we will provide a robust and scalable CDMO solution backed by world-class quality, compliance and manufacturing excellence. We believe this partnership creates a strong foundation for sustainable growth and long-term value creation for our customers and both organizations."



About Neuland Laboratories Limited (BSE: 524558, NSE: NEULANDLAB)

Neuland Laboratories Limited [Neuland] is a specialist API CDMO partner for big pharma and biotech – delivering world-class process development and commercial supply services for the most complex molecules and New Chemical Entities. Serving clients in over 80 countries, Neuland operates three US FDA and EU GMP-compliant facilities in India, with a combined reactor capacity of approximately 1218kL. The CDMO invested in a new commercial scale peptide facility in 2026, and is opening a large, dedicated R&D process development centre in Hyderabad. The company has filed over 1000 DMFs globally – as it also supports generic drug substance providers – and offers more than 100 APIs across multiple therapeutic areas.

About Gland Pharma Limited (BSE: 543245, NSE: GLAND)

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and has an excellent track record in developing, manufacturing, and marketing sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. It also enjoys the distinction of having pioneered Heparin technology in India.

